Seoul National University

Viromed Co., Ltd.

Apharma

Cellid Co., Ltd.

Yeonseok Chung

Chang-Yuil Kang

Tae Hyun Kim

Sun-Young Chang

Won Keun Kim

Sang Geon Kim

Dong-Hyeon Kim

Joon Youb Lee

Hyun-Jeong Ko

Yeon-Jeong Kim

Kyung-Chul Lee

Byung-Seok Kim

Sung-Youl Ko

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance

The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.

Her-2/neu DNA vaccine having anti-cancer activity

The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with &#x3b1;-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

B cell-based vaccine loaded with the ligand of natural killer T cell and antigen

Growing community of inventors

Seoul, South Korea

Yeonseok Chung